Telix Pharmaceuticals (TLX) Projected to Post Earnings on Wednesday

Telix Pharmaceuticals (NASDAQ:TLX) is expected to release its H1 2025 earnings data before the market opens on Wednesday, August 20th. Analysts expect Telix Pharmaceuticals to post earnings of $0.22 per share and revenue of $316.69 million for the quarter.

Telix Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ:TLX opened at $10.82 on Wednesday. Telix Pharmaceuticals has a 52-week low of $10.70 and a 52-week high of $30.36. The business’s 50 day moving average is $15.35 and its 200 day moving average is $16.65. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. William Blair restated an “outperform” rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. HC Wainwright initiated coverage on Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a “buy” rating and a $23.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Thursday, June 12th.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.